Tag: lsd

Using Psychedelics Is Tied To 25% Lower Likelihood Of ‘Frequent Bad Headaches,’ Study Shows

People who have used so-called “classic psychedelics” such as psilocybin or LSD are less likely to report having frequent bad headaches, a new study concludes.

The results, authors wrote this month in the Journal of Pharmacology, “add to the literature suggesting classic psychedelics as a possible future prophylactic treatment option for primary headache disorders.”

Researchers gathered data from 11,419 records collected from 1999 to 2000 as part of the British Child Development Study 1958, which follows a cohort of people born over the course of a single week in March 1958.

Specifically, they looked at responses to three questions: “Do you often have bad headaches?” “Have you ever tried LSD, also known as acid or trips?” and “Have you ever tried magic mushrooms?”

The team’s analysis showed that “lifetime use of classic psychedelics was associated with 25% lower odds of having frequent bad headaches.”

There are, of course, limitations as to what conclusions can be drawn from the observational nature of the study.

“Although we have proposed a direction of association, we cannot draw any causal inferences about the association between lifetime use of classic psychedelics and frequent bad headaches,” they wrote. “It is possible that the negative association found is a result of people suffering from frequent bad headaches abstaining from the use of classic psychedelics.”

Data from the same survey, for example, showed that low alcohol use was associated with higher likelihood of frequent bad headaches. In that case, authors interpreted the finding by saying it “may be explained by individuals experiencing frequent bad headaches choosing to abstain from alcohol,” noting that alcohol is understood to be a trigger for headaches.

Overall, 16 percent of people in the survey reported frequent bad headaches. Of those, 71 percent were female and 29 percent were male. Lifetime use of classic psychedelics, meanwhile, was reported by 6.5 percent of people with frequent bad headaches and 8.6 percent of those without.

Notably, when the research team divided reports by sex, they noticed a stronger association between psychedelics use and headaches among female respondents.

Keep reading

Operation Midnight Climax: A CIA Sex, Drugs and Surveillance Program

Key Takeaways

  • Operation Midnight Climax was a CIA experiment in San Francisco from the 1950s to 1960s testing the effects of LSD and sex on men’s behavior.
  • The experiment was part of the larger MKULTRA program aimed at developing mind-control capabilities.
  • The CIA used prostitutes to lure men to a wired bordello for surveillance, but the unethical program was terminated in 1967.

From the mid-1950s to the early 1960s, men in San Francisco who patronized prostitutes ran the risk of becoming unwitting participants in a clandestine CIA experiment. It was designed to test whether the combination of sex and the hallucinogenic drug LSD might influence the men to reveal information that the government wanted. What information, nobody is really sure.

The experiment, known as Operation Midnight Climax inside the CIA, was part of a larger research program code-named MKULTRA. The agency launched MKULTRA out of worries that the Soviet Union had developed a mind-control drug.

CIA officials had observed the vacant gaze and trance-like behavior of Hungarian cleric Cardinal József Mindszenty at a show trial in Budapest in 1949. They were convinced that his confession had been extracted with chemicals, according to a 1977 New York Times article and decided that the U.S. needed to have similar capabilities.

Keep reading

First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD).

Drugmaker MindMed says that the trial, dubbed Voyage, is eventually expected to enroll about 200 people in the U.S. and will compare the effects of its proprietary LSD product to a placebo. A second Phase 3 trial, called Panorama, will also be conducted in both the U.S. and Europe and is expected to kick off in the first half of next year.

“Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people in the U.S. living with GAD,” MindMed’s chief medical officer, Daniel R. Karlin, said in a statement released on Monday. “Building on our scientifically rigorous Phase 2b study, which demonstrated efficacy that far exceeds today’s standard of care and a favorable tolerability profile, our Phase 3 studies are designed to adhere to the highest clinical and ethical standards and are in alignment with guidance from the U.S. Food and Drug Administration.”

In March of this year, the Food and Drug Administration (FDA) granted MindMed’s LSD product “breakthrough therapy” status as a treatment for GAD. That followed a Phase 2 trial showing that a single oral dose of LSD led to “clinically and statistically significant” reductions in anxiety scores 12 weeks after administration, with 65 percent of participants showing a clinical response and 48 percent in clinical remission following the treatment.

Breakthrough drug status is meant to recognize the therapeutic promise of an emerging substance or therapy as well as speed the research and development of treatments that fill an unmet need. MDMA and psilocybin have also previously been awarded the designation.

The new research will use dissolvable oral tablets of the drug, MM120 ODT, or lysergide D-tartrate, which MindMed describes as a “proprietary and pharmaceutically optimized form of LSD.”

The first Phase 3 study, Voyage, will last a year and consist of two parts: a 12-week randomized, double-blind, placebo-controlled study to see how LSD affects anxiety symptoms. That will be followed by a 40-week extension period, during which participants can access open-label treatment with the drug based on the severity of their anxiety symptoms.

LSD has a noticeable subjective effect on sensation and cognition, which means it’s likely participants will know whether they received the psychedelic or a non-psychoactive placebo.

Keep reading

New Study Finds One Dose of LSD Could Effectively Treat Anxiety in Many Patients

After years of criminalization and marginalization, scientists have begun looking at LSD’s medical benefits more closely, so much so that the Food and Drug Administration just issued a groundbreaking stamp of approval. 

Biopharmaceutical company Mind Medicine announced March 7 that the FDA has awarded “breakthrough therapy” status to its trial of patients using MM120 (lysergide D-tartrate) to treat anxiety. MindMed chief medical officer Daniel Karlin explained what the trial approval means going forward. “A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need with morbidity and mortality associated with it,” he told CNN. The move allows the FDA to “engage more closely in drug development” and speeds up the road to final approval as the agency is involved throughout the process. 

MM120 is the codename for MindMed’s lysergide D-tartrate compound, which resembles and delivers similar effects to lysergic acid diethylamide, known more commonly as LSD. In its ongoing trial, which kicked off in 2022, MindMed has so far found that a single dose of MM120 led to a 48-percent rate of remission from generalized anxiety disorder after 12 weeks following the drug’s administration. Scientists also noted significantly improved clinical signs of generalized anxiety disorder among 65 percent of patients within three months. 

“The clinical improvement for many patients was more than double what we see with today’s standard of care,” Karlin said. “This occurred at all levels of anxiety, from moderate all the way up to severe.”

Keep reading

Single LSD dose provides lasting anxiety relief: Research

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to an LSD formula to treat generalized anxiety disorder after an initial study has shown that a single dose of the drug could provide lasting relief.

The LSD therapy developed by Mind Medicine Inc. (MindMed) must still go through the standard FDA approval process and will soon enter Phase 3 clinical trials.

The study that prompted FDA advancement found the drug was “generally well-tolerated with most adverse events rated as mild to moderate, transient and occurring on dosing day, and being consistent with expected acute effects of the study drug,” according to a release on the findings.

The most common adverse effects on the initial “dosing day” — or when patients were first given the drug — included hallucinations, euphoric mood, abnormal thinking, headache, dizziness and nausea, among others.

The company plans to meet for an update with the FDA in the coming months and begin an expanded clinical program in the second half of the year.

MindMed, a pharmaceutical company focused on developing psychedelic drugs into medicines, has spent years researching possible medicinal uses for LSD, an illicit drug that has never been approved for medicinal use. The specific LSD formula from the study is dubbed MM120.

Keep reading

Recommended reading…

Get it HERE.

“A journalist’s twenty-year fascination with the Manson murders leads to “gobsmacking” (The Ringer) new revelations about the FBI’s involvement in this “kaleidoscopic” (The New York Times) reassessment of an infamous case in American history.

Over two grim nights in Los Angeles, the young followers of Charles Manson murdered seven people, including the actress Sharon Tate, then eight months pregnant. With no mercy and seemingly no motive, the Manson Family followed their leader’s every order — their crimes lit a flame of paranoia across the nation, spelling the end of the sixties. Manson became one of history’s most infamous criminals, his name forever attached to an era when charlatans mixed with prodigies, free love was as possible as brainwashing, and utopia — or dystopia — was just an acid trip away.

Twenty years ago, when journalist Tom O’Neill was reporting a magazine piece about the murders, he worried there was nothing new to say. Then he unearthed shocking evidence of a cover-up behind the “official” story, including police carelessness, legal misconduct, and potential surveillance by intelligence agents. When a tense interview with Vincent Bugliosi — prosecutor of the Manson Family and author of Helter Skelter — turned a friendly source into a nemesis, O’Neill knew he was onto something. But every discovery brought more questions:

  • Who were Manson’s real friends in Hollywood, and how far would they go to hide their ties?
  • Why didn’t law enforcement, including Manson’s own parole officer, act on their many chances to stop him?
  • And how did Manson — an illiterate ex-con — turn a group of peaceful hippies into remorseless killers?

O’Neill’s quest for the truth led him from reclusive celebrities to seasoned spies, from San Francisco’s summer of love to the shadowy sites of the CIA’s mind-control experiments, on a trail rife with shady cover-ups and suspicious coincidences. The product of two decades of reporting, hundreds of new interviews, and dozens of never-before-seen documents from the LAPD, the FBI, and the CIA, Chaos mounts an argument that could be, according to Los Angeles Deputy District Attorney Steven Kay, strong enough to overturn the verdicts on the Manson murders. This is a book that overturns our understanding of a pivotal time in American history.”

Margaret Mead’s LSD Memo

With her paper-cluttered desk spotlit underneath a pendant lamp, Margaret Mead’s office in the western turret in the American Museum of Natural History resembled a Broadway theater set. All around her in the shadows hung masks and carved figures, as if the museum dioramas from the floors below had begun to creep into her workspace.

Back in her spiritual home after spending the last six months of 1953 in Manus, she felt refreshed, confident. She was already thinking through her book about her experience; New Lives for Old would be the title, and it would describe the Noise, an apocalyptic religious movement which spread through the island of Manus, which lies northeast of New Guinea, in the aftermath of World War II. In 1947, a prophet had emerged on Manus who predicted a coming age of abundance, even immortality. But first, the old ways had to be cast out. Reports poured in of visionary experiences, trance states, even seizures. Hats of colonial officials were ritually burned, and a coming age of abundance was proclaimed. Mead found the Noise fascinating because she saw it as a prelude to other new cultural forms which she believed would appear elsewhere as a response to the rapid changes of the 20th century—including in the United States. She saw the movement in relatively benign terms. True, it really was an apocalyptic cult, she wrote, complete with mystical “prophetic dreams” and the promise of “a utopia to be immediately established on earth.” But who said utopian dreams were entirely bad?

Keep reading

THE WEIRD AND WONDERFUL WORLD OF LSD

LSD is a drug which has had a bizarre inception and nuanced history. What began as a pharmacological experiment rapidly evolved into a substance which was used for a wide range of uses. From groundbreaking psychiatric work all the way to abuse in mind control military projects, let’s dive into some of the most significant examples of psychedelics’ use in society since its creation.

Hofmann’s Accidental Ingestion

Dubbed as the father of the psychedelic movement due to his work on the synthesis of LSD, Albert Hofmann was the first to produce and ingest LSD. Albert Hofmann first synthesised Lysergic Acid Diethylamide (LSD) in November 1938 when studying the medicinal properties of the ergot fungus and the Mediterranean squill. Ergot is a fungus which grows on rye and can infect the grain causing muscle spasms, delusions, hallucinations, gangrenous symptoms and ultimately death to those who consume it. This process has been linked to plagues and famines which have killed hundreds of thousands of people in the past. 

Hofmann’s boss, Arthur Stoll, managed to isolate the toxic compounds in ergot: ergotamine and ergobasine. By utilising Aotamine, the medicinal compound in ergot, Stoll was able to produce medicines for his Swiss pharmaceutical company Sandoz. 

Hofmann originally intended for LSD to be used as a respiratory and circulatory stimulant. However, when he accidentally absorbed the drug in his lab in 1943, he discovered that it had a far more powerful impact on his state of consciousness. Hofmann originally was unsure of how he had experienced the effects, and believed that LSD couldn’t have been the cause for his symptoms as he had been meticulous in avoiding contamination due to his knowledge of the lethality of ergot. However, he attempted to reproduce his effects by consuming what he believed to be a miniscule dose of LSD to test whether it was the cause.

Keep reading

Psilocybin, LSD And Other Psychedelics Improve Sexual Satisfaction For Months After Use, New Study Finds

Psychedelic substances, including psilocybin mushrooms, LSD and others, may improve sexual function—even months after a psychedelic experience, according to a new study.

The findings, published on Wednesday in Nature Scientific Reports, are based largely on a survey of 261 participants both before and after taking psychedelics. Researchers from Imperial College London’s Centre for Psychedelic Research then combined those responses with results of a separate clinical trial that compared psilocybin and a commonly prescribed selective serotonin reuptake inhibitor (SSRIs) for treating depression.

Authors say it’s the first scientific study to formally explore the effects of psychedelics on sexual functioning. While anecdotal reports and and qualitative evidence suggest the substances may be beneficial, the study says, “this has never been formally tested.”

“It’s important to stress our work does not focus on what happens to sexual functioning while people are on psychedelics, and we are not talking about perceived ‘sexual performance,’” said Tommaso Barba, a PhD student at the Centre for Psychedelic Research and the lead author of the study, “but it does indicate there may be a lasting positive impact on sexual functioning after their psychedelic experience, which could potentially have impacts on psychological wellbeing.”

Keep reading